Deep Fission Signs Binding 25-Year Master Energy Purchase Agreement for Planned Commercial Project

Deep Fission (FISN) rose about 8.1% after it said the U.S. Department of Energy approved its Nuclear Safety Design Agreement for its underground gravity SMR. The company said the approval supports advancing its reactor design. The move is tied to DOE safety-design clearance, which investors may view as progress toward development.

Deep Fission Inc., which is developing an underground Gravity Reactor in Parsons, Kansas, plans an IPO of 2.5 million shares to raise more than $40 million, according to an SEC filing. It previously targeted about 6 million shares at $24–$26, but revised the offering to $16–$18. The company seeks Nasdaq listing under FISN and says its reactor is unproven; it drilled its first well and plans NRC licensing in early 2027.

Beam Therapeutics reported positive results from a pivotal trial of its base editing therapy, risto-cel, for sickle cell disease, meeting primary and secondary endpoints. The company plans to seek FDA approval by year-end. Beam's shares fell 10% on the news, despite the positive trial outcome.

Morgan Stanley kept Hims & Hers Health at Equal-Weight, cutting its price target to $25 from $28, a 10.7% reduction. This implies a 9.0% upside from the Nov 9 close of $22.94, according to the bank.

Morgan Stanley kept Bicara Therapeutics at Overweight but reduced its price target to $30 from $41, citing a 26.8% decrease. The new target suggests a 200.6% upside from the Nov 9 close of $9.98. Recent analyst price targets for the company range from $8 to $43.

Goldman Sachs, Citigroup, Banco Santander, and Deutsche Bank, among others, have committed $270 million to a joint stablecoin venture called Project Faro. The U.S.-incorporated issuer aims to launch a dollar-pegged token by mid-2027, with plans to expand into other G7 currencies. The venture targets institutional and retail markets, focusing on cross-border transactions and digital asset settlements under regulatory frameworks like the U.S. GENIUS Act and Europe's MiCA.